Benchling vs Noom: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Benchling and Noom.
Benchling
Life science R&D platform combining electronic lab notebook, molecular biology tools, and LIMS (lab information management) for biopharma, biotech, and agricultural science.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Noom
AI-powered weight management platform combining psychology-based behaviour change coaching with personalised meal and exercise plans.
No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Healthcare tech with long sales cycles; ISO/NSO options; regulatory milestones drive value
Key differences for employees
Equity structure
Benchling grants ISO/NSO with strike prices ranging from $18–$30 depending on your grant year. Noom grants ISO/NSO with strike prices from $14–$22.
Secondary market signal
Benchling has no recent verified secondary signal — only the primary round ($6.1B) is shown. Noom has no recent verified secondary signal. A higher secondary premium typically signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Benchling runs at $0.1B ARR, growing +30% YoY (solid). Noom runs at $0.6B ARR, growing +20% YoY (solid). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Benchling: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Noom: No near-term IPO expected. Company likely 2028+ at earliest; patient equity required.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value using peer-multiple, secondary-market, time-decay, and sector-momentum methods.